Literature DB >> 18480483

Total hip arthroplasty in patients with bone deficiency of the acetabulum.

Robert H Choplin1, Christopher N Henley, Eric M Edds, William Capello, James L Rankin, Kenneth A Buckwalter.   

Abstract

Total hip replacement (THR) requires revision in only a minority of cases (approximately 17% of prosthetic hips fail), but when THR failures occur there may be significant acetabular bone deficiency. There is a variety of surgical hardware and strategies available to address this problem. The causes of primary THR revision include aseptic loosening or particle disease, infection, recurrent dislocation, implant failure, periprosthetic fracture, and leg length discrepancy. Almost all patients who need THR revision undergo a standard radiographic evaluation of the pelvis and hip. In general, CT is an excellent tool for evaluating loosening of the prosthesis caused by either mechanical reasons or infection, and MR imaging is best suited for evaluating the soft tissues surrounding the prosthesis. Nuclear medicine studies are performed when results of CT and MR imaging are inconclusive. When patients are evaluated for revision THR, radiologists must check for acetabular cup loosening, the amount and type of bone stock loss, the amount of component migration, and the presence or absence of liner wear. Before revision hardware is placed, bone stock loss must be repaired, either by using bone grafting or by placing accessory acetabular hardware such as cups, rings, or cages. The long-term success of revision acetabular surgery varies; there is acetabular cup presence at 5 years after surgery in 60%-94% of cases. Complications include postoperative infections, repeat liner wear, bone graft failure, periprosthetic or prosthetic fractures, dislocation, vascular injury, and nerve injury. Copyright RSNA, 2008.

Entities:  

Mesh:

Year:  2008        PMID: 18480483     DOI: 10.1148/rg.283075085

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  7 in total

1.  Total hip prosthesis CT with single-energy projection-based metallic artifact reduction: impact on the visualization of specific periprosthetic soft tissue structures.

Authors:  Pedro Augusto Gondim Teixeira; Jean-Baptiste Meyer; Cedric Baumann; Ariane Raymond; François Sirveaux; Henry Coudane; Alain Blum
Journal:  Skeletal Radiol       Date:  2014-06-10       Impact factor: 2.199

Review 2.  Clinical evaluation and surgical options in acetabular reconstruction: A literature review.

Authors:  Asim Qamar Ahmad; Ran Schwarzkopf
Journal:  J Orthop       Date:  2015-11-02

3.  Segmental acetabular rim defects, bone loss, oversizing, and press fit cup in total hip arthroplasty evaluated with a probabilistic finite element analysis.

Authors:  Farid Amirouche; Giovanni F Solitro; Amit Walia; Mark Gonzalez; Aimee Bobko
Journal:  Int Orthop       Date:  2016-12-23       Impact factor: 3.075

4.  Factors influencing inpatient rehabilitation length of stay following revision hip replacements: a retrospective study.

Authors:  So-Mei Teresa Yeung; Aileen M Davis; Rajka Soric
Journal:  BMC Musculoskelet Disord       Date:  2010-10-28       Impact factor: 2.362

5.  Evaluation of the feasibility of acetabular cup pre-determination in revision total hip arthroplasty via X-ray of the bone stock of the anterosuperior acetabulum.

Authors:  Jingwei Zhang; Keyu Kong; Yingjun Chi; Xiaoliang Liu; Yiming Zeng; Huiwu Li
Journal:  J Orthop Surg Res       Date:  2021-10-14       Impact factor: 2.359

Review 6.  Imaging in Hip Arthroplasty Management Part 2: Postoperative Diagnostic Imaging Strategy.

Authors:  Charles Lombard; Pierre Gillet; Edouard Germain; Fatma Boubaker; Alain Blum; Pedro Augusto Gondim Teixeira; Romain Gillet
Journal:  J Clin Med       Date:  2022-07-29       Impact factor: 4.964

7.  Primary or revision arthroplasty with an integrated acetabular cup-MUTARS® RS cup system.

Authors:  Maren Janko; René Verboket; Maria Genari; Johannes Frank; Ingo Marzi
Journal:  Eur J Trauma Emerg Surg       Date:  2022-03-31       Impact factor: 2.374

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.